Clinical trialNCT04849364TerminatedPhase 2Interventional

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

SponsorBryan Schneider, MDEnrollment52Breast CancerTriple Negative Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms based on plasma ctDNA positivity and genomic marker(s).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Bryan P Schneider, MD
Indiana University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Georgetown University
Washington D.C., District of Columbia, United States
Memorial Healthcare System
Hollywood, Florida, United States
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States
Summit Health
Berkeley Heights, New Jersey, United States
Novant Health Cancer Institute
Winston-Salem, North Carolina, United States
Mays Cancer Center at Ut Health San Antonio
San Antonio, Texas, United States
University of Wisconsin
Madison, Wisconsin, United States
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Advocate Aurora Research Institute (illinois)
Wauwatosa, Wisconsin, United States
Aurora Health Care
Wauwatosa, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Capecitabine →Inavolisib →Pembrolizumab →Talazoparib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Aug 2021
Primary completion: 24 Oct 2024
Completion: 2 Dec 2024
Last update posted: 31 May 2025
Registered enrollment: 52
Registry id: NCT04849364

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.